ABOUT US
CEO MESSAGE
FREST was established to provide new medical values by utilizing its unique technology to edit gene structures at the mRNA level.
The history of medicine is also the history of technology. The development of synthesis technology has contributed greatly to the establishment of small molecule drugs, and the evolution of genetic engineering has contributed greatly to the leap forward in biologics.
Our "RNA editing technology" is the next generation technology after genome editing technology, and expected to open a new page of drug discovery by the development of drugs for diseases without an effective treatment, such as many genetic diseases.
The applications of RNA editing technology are wide-ranging. However, we cannot maximize the value of the technology on our own. We will make the most of our flexible mobility to collaborate with healthcare professionals, researchers, and pharmaceutical companies to expand the applications of RNA editing technology. We do our best to deliver medicines to patients suffering from diseases as quickly as possible.
CEO Nobuaki Takahashi, Ph.D.
Our Team
Nobuaki Takahashi, Ph.D.
Chief Executive Officer
Takahashi joined FREST as CEO
in August 2022 and leads all aspects of management and R&D. Previously, he
worked in Kyowa Kirin where he held various important positions such as the
head of RNA business group since 2019, and the head of antibody research group
since 2012. He spent a few years working at Gemini Science, Kyowa Kirin's
overseas R&D subsidiary since 1998. He also served as CTO of a biotech. He holds
PhD in Science from Osaka University
Masatora Fukuda
Associate Professor Fukuoka University, Faculty of Science
Founder, Scientific Advisor
Fukuda has been engaged in RNA editing research over a decade
and he is one of leading scientists in this field, with many collaborations
with pharmaceutical companies. He founded FREST in 2020 based on his research
outcomes. He joined Faculty of Science at Fukuoka University since 2010 after
serving Kyoto University as a researcher and assistant professor. He holds a BS
in Physics from Kwansei Gakuin University and a MS, PhD in Energy Science from Kyoto University.
Campany profile
Company:
FREST Inc.
Founded:
June 23, 2020
Capital:
90,000,000 JPY
Founder:
Masatora
Fukuda (Associate Professor, Fukuoka Univ. Faculty of Science)
CEO:
Nobuaki Takahashi
Shareholders:
Masatora Fukuda
Shinsei Capital Partners (New Life Science I Investment Limited Partnership）
Officers and employees
Head office & Laboratory:
2-26-1 Muraokahigashi, Fujisawa-shi, Kanagawa 251-8555
Shonan Health Innovation Park (iPark)
History
Prof. Fukuda founded FREST
▶ Dec 2020
Recognized as a Universty launched venture by Fukuoka University
▶ Feb 2021
FREST entered into a license agreement and research collaboration with Fukuoka University
FREST raised Seed funding round from Shinsei Capital Partners
▶ Aug 2022
Takahashi joined FREST as CEO FREST transferred its HQs to LINK-J
▶ Dec 2023
FREST raised the second Seed funding round from Shinsei Capital Partners
▶ Dec 2023
Laboratory opened in Shonan iPark
▶ Feb 2024
Head office relocated to Shonan iPark
▶ May 2024
FREST raised funding from Shinsei Capital Partners by CB